Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases.
The company’s marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.
More News from Barchart
These efforts have helped the company reach a market cap of about $25.3 billion, placing it above the $10 billion threshold commonly used to classify large stocks.
The stock is currently trading just 4.3% below its 52-week high of $132.60, reached in July. Its strength has been particularly evident in recent months, with Incyte shares gaining 22.5% over the past three months and outperforming the State Street SPDR S&P Biotech ETF ( XBI ), which has risen 11% over the same period.
The stock’s performance has remained solid over longer time frames, even as it has trailed broader biotech ETFs. Over the past 52 weeks, Incyte shares have risen 49.8%, compared to a 66.4% rise for XBI. Additionally, INCY shares are up 28.5% year-to-date (YTD), while the ETF is up 32.8%.
From a technical perspective, the new strength is also reflected in Incyte’s moving average. Since June, the stock has continued to trade above its 50-day moving average of $122.72 and its 200-day moving average of $105.88, indicating sustained upward momentum.
Incyte’s recent rally reflects improved fundamentals and a stronger biotech backdrop, with investor interest in the drug development pipeline and innovation gaining momentum. The company’s growth prospects have improved along with better performance in its commercial portfolio, providing further support for the stock.
Q2 FY2026 net sales increased 40.5% year-on-year (YOY) to $1.5 billion, while sales excluding a one-time benefit of $246 million from Opzelura, a topical skin care drug, rose 17%. Jakafi grew 6.9% YOY to $816.7 million, and Incyte’s hematology and oncology portfolio grew 69%. Going forward, management also raised its FY2026 sales guidance to $5.13 billion-$5.26 billion.